Nivolumab
Von Hippel-Lindau Disease
Merck Sharp & Dohme LLCmonoclonal_antibodyPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
9 Active assets in the Von Hippel-Lindau Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Belzutifan Merck Sharp & Dohme LLC | Phase 3 | BB |
Palbociclib Merck Sharp & Dohme LLC | Phase 3 | B |
Lenvatinib Merck Sharp & Dohme LLC | Phase 3 | B |
Cabozantinib Merck Sharp & Dohme LLC | Phase 3 | B |
Everolimus Merck Sharp & Dohme LLC | Phase 3 | B |
View all 16 →
Same molecule, other indications
Nivolumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →